|Systematic (IUPAC) name|
|Molar mass||511.617 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
DS-1 is a drug from the imidazopyridine family which is the first drug developed that acts as a GABAA receptor agonist selective for the α4β3δ subtype, which is not targeted by other GABA agonists such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.
|This pharmacology-related article is a stub. You can help ssf by expanding it.|
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, Belelli D, Lambert JJ. Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus. Neuropharmacology. 2009 Jan;56(1):182-9. PMID 18762200